Lemtrada
Named-patient access overview. Lemtrada is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Lemtrada (alemtuzumab) is a humanised anti-CD52 monoclonal antibody developed by Sanofi-Genzyme. The US Food and Drug Administration approved Lemtrada in November 2014 for adults with relapsing forms of multiple sclerosis, generally reserved for patients who have had an inadequate response to two or more disease-modifying therapies given its risk profile. Dosing is intravenous in a pulsed schedule, with five consecutive daily infusions in the first course and three consecutive daily infusions in the second course twelve months later, plus optional additional courses based on clinical response. Treatment is administered in a hospital or specialised infusion centre under neurology supervision, with mandatory monthly laboratory monitoring and a long REMS-style monitoring period for autoimmune, infection, and malignancy risks.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Lemtrada
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Lemtrada is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Lemtrada in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Lemtrada
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.